Reviewing uniQure N.V. (QURE)’s and OPKO Health Inc. (NASDAQ:OPK)’s results

This is therefore a comparing of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in uniQure N.V. (NASDAQ:QURE) and OPKO Health Inc. (NASDAQ:OPK). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
uniQure N.V. 11.28M 209.76 83.30M -2.69 0.00
OPKO Health Inc. 990.27M 1.50 153.04M -0.52 0.00

In table 1 we can see uniQure N.V. and OPKO Health Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
uniQure N.V. -738.48% -58.5% -35.9%
OPKO Health Inc. -15.45% -16.4% -11.8%

Volatility & Risk

uniQure N.V. has a 1.07 beta, while its volatility is 7.00%, thus making it more volatile than S&P 500. OPKO Health Inc.’s 89.00% more volatile than S&P 500 volatility due to the stock’s 1.89 beta.


The Current Ratio and Quick Ratio of uniQure N.V. are 7.6 and 7.6 respectively. Its competitor OPKO Health Inc.’s Current Ratio is 0.9 and its Quick Ratio is 0.8. uniQure N.V. can pay off short and long-term obligations better than OPKO Health Inc.

Analyst Ratings

uniQure N.V. and OPKO Health Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
uniQure N.V. 0 0 7 3.00
OPKO Health Inc. 0 0 0 0.00

uniQure N.V. has a 16.44% upside potential and an average target price of $74.

Insider & Institutional Ownership

The shares of both uniQure N.V. and OPKO Health Inc. are owned by institutional investors at 78.9% and 24.9% respectively. About 2.2% of uniQure N.V.’s share are held by insiders. Competitively, 5.7% are OPKO Health Inc.’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
uniQure N.V. 6.3% 73.4% 107.66% 40.7% 137.94% 106.07%
OPKO Health Inc. -5.99% -27.45% -22.83% -54.36% -29.74% -11.3%

For the past year uniQure N.V. had bullish trend while OPKO Health Inc. had bearish trend.


On 6 of the 11 factors OPKO Health Inc. beats uniQure N.V.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.